Evidence map›Paper›PMID 42871871›Full record

ArticleCell biomaterials2026

Oxygen-generating cryogel vaccines help overcome tumor antigen tolerance and induce durable antitumor immunity in prostate cancer.

Alexandra Nukovic, Khushbu Bhatt, Thibault Colombani, Emilia Todorovic, Lucy M Williamson, Brittany Noonan, Enrique M Chang, Laura Losada Miguens, Michail Sitkovsky, Sidi A Bencherif and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alexandra NukovicDepartment of Chemical Engineering, Northeastern University, Boston, MA 02115, USA.
Khushbu BhattDepartment of Pharmaceutical Sciences, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA.
Thibault ColombaniDepartment of Chemical Engineering, Northeastern University, Boston, MA 02115, USA.
Emilia TodorovicDepartment of Chemical Engineering, Northeastern University, Boston, MA 02115, USA.
Lucy M WilliamsonNew England Inflammation and Tissue Protection Institute, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA.
Brittany NoonanNew England Inflammation and Tissue Protection Institute, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA.
Enrique M ChangNew England Inflammation and Tissue Protection Institute, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA.
Laura Losada MiguensNew England Inflammation and Tissue Protection Institute, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA.
Michail SitkovskyNew England Inflammation and Tissue Protection Institute, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA.
Sidi A BencherifDepartment of Chemical Engineering, Northeastern University, Boston, MA 02115, USA.
Stephen M HatfieldDepartment of Chemical Engineering, Northeastern University, Boston, MA 02115, USA.

Funding

Overcoming vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapyR01EB027705 · NIBIB · NORTHEASTERN UNIVERSITY · PI HATFIELD, STEPHEN MATTHEW · 2021 to 2024
$1.9M
NIBIB NIH HHS R01 EB027705
6 · The paper itself

Abstract

Therapeutic cancer vaccines represent a promising approach to boost patients' own immune system to fight cancer; however, they have shown limited success in clinical trials largely due to insufficient antigen delivery to overcome tolerance and hypoxia-mediated immunosuppression. Cryogel-based delivery scaffolds offer a promising platform for cancer vaccines due to their biocompatibility and macroporous structure, enabling effective delivery to infiltrating antigen-presenting cells. However, these systems are limited by rapid, diffusion-mediated burst release of encapsulated proteins and local hypoxia-driven immunosuppression. Click conjugation of a tumor-associated protein within cryogel-based vaccines, combined with an O

Indexed as

cancercontrolled releasecryogeloxygentherapeutic vaccine

Identifiers

PMID42871871
PMCPMC13660792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.